Moberg Pharma Q1’22: Real progress in the Quarter - Redeye

Redeye’s comments on the Q1 report that was published earlier this morning. The main events during the quarter have already been well communicated. These are the submittal of the registration in Europe and regulatory filing for the next clinical Phase 3 study in the US. The results for the quarter were as expected with no sales and costs well maintained.

Länk till analysen i sin helhet: https://www.redeye.se/research/841337/moberg-pharma-q122-real-progress-in-the-quarter?utm_source=finwire&utm_medium=RSS